Caribou Biosciences
Biotechnology company focused on genome engineering and developing technology-based solutions for cells.
HQ location
Berkeley, United States
Website
Launch date
Employees
Market cap
$119m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | N/A | $125m | Post IPO Equity |
| Total Funding | 000k | ||
Anterra Capital(exited)
Heritage Group(exited)
Maverick Capital(exited)
Marc Bell Capital(exited)
E-Merge(exited)
Novartis(exited)
David Beyer(exited)
Maverick Ventures(exited)
F-Prime(exited)
Mission Bay Capital(exited)
Pontifax AgTech(exited)
Genoa Ventures(exited)
Farallon Capital Management(exited)
PFM Health Sciences(exited)
Ridgeback Capital(exited)
Adage Capital(exited)
Avego Bioscience Capital(exited)
Avidity Partners(exited)
Invus(exited)
Janus Henderson Investors(exited)
LifeSci Venture Partners(exited)
Monashee Investment Management(exited)
Point72 Ventures(exited)
Tekla Capital Management(exited)
The Leukemia & Lymphoma Society(exited)
Heritage Medical Systems(exited)
AbbVie(exited)
Eight Roads Ventures(exited)
Meadow Ventures(exited)
National Science Foundation(exited)
Philip Austin(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (22 %) | 44 % | 149 % | (71 %) | (5 %) | 128 % | 13 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (710 %) | (767 %) | (326 %) | (1628 %) | (1482 %) | (815 %) | 20 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (697 %) | (718 %) | (296 %) | (1492 %) | (1490 %) | (656 %) | (527 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 544 % | 594 % | 325 % | 1302 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Caribou Biosciences
Edit
exited